{
  "id": "2247620991_3",
  "title": "全球首个！国产 CCR8 多肽抑制剂获批临床",
  "content": "<div class=\"rich_media_content js_underline_content autoTypeSetting24psection\" id=\"js_content\">\n <section data-mpa-action-id=\"mcn6zxwd18v6\" data-pm-slice=\"0 0 []\" style=\"text-align: center;margin-left: 8px;margin-right: 8px;\">\n  <a class=\"weapp_image_link js_weapp_entry\" data-miniprogram-appid=\"wx33d4c3735820a33e\" data-miniprogram-applink=\"\" data-miniprogram-imageurl=\"https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8vROvmPqd90D6qZZzHhQwNBck2THhGajmUBOiaz7dPLTUw4LGrUazBPtVTYLDmWibvichjicrGCtRyWDg/640?wx_fmt=png&amp;from=appmsg\" data-miniprogram-nickname=\"Insight医药情报助手\" data-miniprogram-path=\"pages/index/index\" data-miniprogram-servicetype=\"0\" data-miniprogram-type=\"image\" style=\"\">\n   <img class=\"rich_pages wxw-img\" data-imgfileid=\"100133179\" data-ratio=\"0.26382978723404255\" data-s=\"300,640\" data-type=\"png\" data-w=\"940\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8vROvmPqd90D6qZZzHhQwNBck2THhGajmUBOiaz7dPLTUw4LGrUazBPtVTYLDmWibvichjicrGCtRyWDg/640?wx_fmt=png&amp;from=appmsg\" type=\"block\"/>\n  </a>\n </section>\n <section data-mpa-action-id=\"mcn6zxwd1qgq\" data-pm-slice=\"0 0 []\" style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;margin-bottom: 24px;\">\n  <span leaf=\"\">\n   <span style=\"font-size: 15px;\" textstyle=\"\">\n    7 月 3 日，\n   </span>\n  </span>\n  <span leaf=\"\">\n   <span style=\"font-size: 15px;\" textstyle=\"\">\n    康缘药业发布公告，宣布其\n   </span>\n  </span>\n  <span leaf=\"\">\n   <span style=\"font-size: 15px;\" textstyle=\"\">\n    1 类化学新药 KYS2301 凝胶\n   </span>\n   <span style=\"font-size: 15px;color: rgb(178, 178, 178);\" textstyle=\"\">\n    （三种规格：1%、3%、5%）\n   </span>\n   <span style=\"font-size: 15px;\" textstyle=\"\">\n    已获药监局批准，同意开展临床，适应症为\n   </span>\n   <span style=\"font-size: 15px;font-weight: bold;\" textstyle=\"\">\n    特应性皮炎\n   </span>\n   <span style=\"font-size: 15px;\" textstyle=\"\">\n    。\n   </span>\n  </span>\n </section>\n <section nodeleaf=\"\" style=\"text-align: center;margin-left: 8px;margin-right: 8px;margin-bottom: 0px;\">\n  <img class=\"rich_pages wxw-img\" data-imgfileid=\"100137323\" data-ratio=\"0.41759259259259257\" data-s=\"300,640\" data-type=\"png\" data-w=\"1080\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8spkkeMz6z17icUbDAyiagMIttObBBP7ibbTBmTvPUoZ5Zr3AfRk4zmOd8egdd5PgRsEWAsFXibHibicChg/640?wx_fmt=png&amp;from=appmsg\" type=\"block\"/>\n </section>\n <section data-mpa-action-id=\"mcn6zxwd1qgq\" data-pm-slice=\"0 0 []\" style=\"margin-left: 8px;margin-right: 8px;line-height: 1.75em;margin-bottom: 24px;text-align: center;\">\n  <span leaf=\"\">\n   <span style=\"font-size: 12px;color: rgb(178, 178, 178);\" textstyle=\"\">\n    截图来源：企业公告\n   </span>\n  </span>\n </section>\n <p style=\"margin-left: 8px;margin-right: 8px;margin-bottom: 24px;line-height: 1.75em;\">\n  <span leaf=\"\">\n   <span style=\"font-size: 15px;\" textstyle=\"\">\n    KYS2301 是\n   </span>\n  </span>\n  <span data-pm-slice='1 1 [\"para\",{\"tagName\":\"section\",\"attributes\":{\"style\":\"margin-left: 8px; margin-right: 8px; line-height: 1.75em; margin-bottom: 24px;\",\"data-mpa-action-id\":\"mcn6zxwd1qgq\",\"data-pm-slice\":\"0 0 []\"},\"namespaceURI\":\"http://www.w3.org/1999/xhtml\"}]' leaf=\"\">\n   <span style=\"font-size: 15px;\" textstyle=\"\">\n    康缘药业\n   </span>\n  </span>\n  <span leaf=\"\">\n   <span style=\"font-size: 15px;\" textstyle=\"\">\n    自主研发的一种新型的趋化因子受体 8\n   </span>\n   <span style=\"font-size: 15px;color: rgb(178, 178, 178);\" textstyle=\"\">\n    （CCR8）\n   </span>\n   <span style=\"font-size: 15px;\" textstyle=\"\">\n    特异性抑制剂，是具有全新氨基酸序列的多肽分子，为\n   </span>\n   <span style=\"font-size: 15px;font-weight: bold;\" textstyle=\"\">\n    全球首个\n   </span>\n   <span style=\"font-size: 15px;\" textstyle=\"\">\n    针对 CCR8 靶点的多肽抑制剂，制剂规格为\n   </span>\n   <span style=\"font-size: 15px;font-weight: bold;\" textstyle=\"\">\n    1%、3% 和 5%\n   </span>\n   <span style=\"font-size: 15px;\" textstyle=\"\">\n    ，适应症定位于\n   </span>\n   <span style=\"font-size: 15px;font-weight: bold;\" textstyle=\"\">\n    特应性皮炎\n   </span>\n   <span style=\"font-size: 15px;\" textstyle=\"\">\n    。\n   </span>\n  </span>\n </p>\n <p style=\"margin-left: 8px;margin-right: 8px;margin-bottom: 24px;line-height: 1.75em;\">\n  <span leaf=\"\">\n   <span style=\"font-size: 15px;\" textstyle=\"\">\n    临床前研究显示，KYS2301 对 CCR8 靶点具有高亲和力，\n   </span>\n   <span style=\"font-size: 15px;font-weight: bold;\" textstyle=\"\">\n    局部皮肤涂抹 KYS2301 凝胶对治疗特应性皮炎具有良好的药效作用\n   </span>\n   <span style=\"font-size: 15px;\" textstyle=\"\">\n    ，毒理学和药代动力学研究证明 KYS2301 凝胶安全性高，系统暴露量低，且反复涂抹耐受性良好。\n   </span>\n  </span>\n </p>\n <p style=\"margin-left: 8px;margin-right: 8px;margin-bottom: 24px;line-height: 1.75em;\">\n  <span leaf=\"\">\n   <span style=\"font-size: 15px;\" textstyle=\"\">\n    公告中指出，截至目前，\n   </span>\n  </span>\n  <span leaf=\"\">\n   <span style=\"font-size: 15px;font-weight: bold;\" textstyle=\"\">\n    全球范围内尚无\n   </span>\n   <span style=\"font-size: 15px;\" textstyle=\"\">\n    针对 CCR8 靶点的多肽药物上市，预计该药具有良好的市场前景。目前该新药累计研发投入约 4493 万元。\n   </span>\n  </span>\n </p>\n <section data-mpa-action-id=\"mcn6zxwdnvx\" style='margin-right: 8px;margin-bottom: 0px;margin-left: 8px;outline: 0px;letter-spacing: 0.544px;text-indent: 0em;color: rgb(34, 34, 34);font-family: -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(255, 255, 255);visibility: visible;line-height: 1.5em;text-align: left;'>\n  <span style=\"outline: 0px;font-size: 12px;visibility: visible;color: rgb(163, 163, 163);\">\n   <strong style=\"outline: 0px;letter-spacing: 0.544px;visibility: visible;\">\n    <span leaf=\"\">\n     封面来源：\n    </span>\n   </strong>\n   <span style='outline: 0px;visibility: visible;font-family: -apple-system, system-ui, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;letter-spacing: 0.544px;'>\n    <span leaf=\"\">\n     企业 Logo\n    </span>\n   </span>\n  </span>\n </section>\n <section data-mpa-action-id=\"mcn6zxwd6v6\" style='margin-right: 8px;margin-bottom: 0px;margin-left: 8px;outline: 0px;letter-spacing: 0.544px;text-indent: 0em;color: rgb(34, 34, 34);font-family: -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(255, 255, 255);visibility: visible;line-height: 1.5em;text-align: left;'>\n  <span style=\"outline: 0px;font-size: 15px;visibility: visible;color: rgb(178, 178, 178);\">\n   <strong style=\"outline: 0px;letter-spacing: 0.544px;font-size: 12px;visibility: visible;\">\n    <span leaf=\"\">\n     免责声明：\n    </span>\n   </strong>\n   <span style=\"outline: 0px;letter-spacing: 0.544px;font-size: 12px;visibility: visible;\">\n    <span leaf=\"\">\n     本文仅作信息分享，不代表 Insight 立场和观点，也不作治疗方案推荐和介绍。如有需求，请咨询和联系正规医疗机构。\n    </span>\n   </span>\n  </span>\n </section>\n <section data-mpa-action-id=\"mcn6zxwd1qft\" style='margin-right: 8px;margin-bottom: 0px;margin-left: 8px;outline: 0px;letter-spacing: 0.544px;text-indent: 0em;color: rgb(34, 34, 34);font-family: -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(255, 255, 255);visibility: visible;line-height: 1.5em;text-align: left;'>\n  <span leaf=\"\">\n   <br/>\n  </span>\n </section>\n <section data-mpa-action-id=\"mcn6zxwdy9d\" style='margin-right: 8px;margin-bottom: 0px;margin-left: 8px;outline: 0px;letter-spacing: 0.544px;text-indent: 0em;color: rgb(34, 34, 34);font-family: -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(255, 255, 255);visibility: visible;line-height: 1.5em;'>\n  <span style=\"outline: 0px;font-size: 12px;color: rgb(178, 178, 178);visibility: visible;\">\n   <strong style=\"outline: 0px;visibility: visible;\">\n    <span leaf=\"\">\n     编辑\n    </span>\n   </strong>\n   <span leaf=\"\">\n    ：ccai\n   </span>\n  </span>\n </section>\n <section data-mpa-action-id=\"mcn6zxwdg8a\" style='margin-right: 8px;margin-bottom: 0px;margin-left: 8px;outline: 0px;letter-spacing: 0.544px;text-indent: 0em;color: rgb(34, 34, 34);font-family: -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(255, 255, 255);visibility: visible;line-height: 1.5em;'>\n  <span style=\"outline: 0px;color: rgb(178, 178, 178);visibility: visible;\">\n   <strong style=\"outline: 0px;visibility: visible;\">\n    <span style=\"outline: 0px;font-size: 12px;visibility: visible;\">\n     <span leaf=\"\">\n      PR 稿对接\n     </span>\n    </span>\n   </strong>\n   <span style=\"outline: 0px;font-size: 12px;visibility: visible;\">\n    <span leaf=\"\">\n     ：微信 insightxb\n    </span>\n   </span>\n  </span>\n </section>\n <section data-mpa-action-id=\"mcn6zxwdwc8\" style='margin-right: 8px;margin-bottom: 24px;margin-left: 8px;outline: 0px;letter-spacing: 0.544px;text-indent: 0em;color: rgb(34, 34, 34);font-family: -apple-system, BlinkMacSystemFont, \"Helvetica Neue\", \"PingFang SC\", \"Hiragino Sans GB\", \"Microsoft YaHei UI\", \"Microsoft YaHei\", Arial, sans-serif;background-color: rgb(255, 255, 255);visibility: visible;line-height: 1.5em;'>\n  <span style=\"outline: 0px;color: rgb(178, 178, 178);visibility: visible;\">\n   <strong style=\"outline: 0px;visibility: visible;\">\n    <span style=\"outline: 0px;font-size: 12px;visibility: visible;\">\n     <span leaf=\"\">\n      投稿\n     </span>\n    </span>\n   </strong>\n   <span style=\"outline: 0px;font-size: 12px;visibility: visible;\">\n    <span leaf=\"\">\n     ：微信 insightxb；邮箱 insight@dxy.cn\n    </span>\n   </span>\n  </span>\n </section>\n <section data-mpa-action-id=\"mcn6zxwd1jej\" nodeleaf=\"\" style=\"text-align: center;margin-left: 8px;margin-right: 8px;margin-bottom: 0px;\">\n  <img class=\"rich_pages wxw-img\" data-imgfileid=\"100133180\" data-ratio=\"0.6319148936170212\" data-s=\"300,640\" data-type=\"png\" data-w=\"940\" src=\"/static/res/logo/https://mmbiz.qpic.cn/mmbiz_png/lVFg8Ny0F8vROvmPqd90D6qZZzHhQwNBzyf7pyZ00Jj17v3UdI4lHwH4Wr619icjjBYhbcBFjPCc9Jkib4472Piag/640?wx_fmt=png&amp;from=appmsg\" type=\"block\"/>\n </section>\n <section>\n  <span leaf=\"\">\n   <br/>\n  </span>\n </section>\n <p style=\"display: none;\">\n  <mp-style-type data-value=\"3\">\n  </mp-style-type>\n </p>\n</div>\n",
  "publish_time": 1751587200,
  "mp_id": "MP_WXS_3975077766",
  "pic_url": "https://mmbiz.qlogo.cn/mmbiz_jpg/lVFg8Ny0F8spkkeMz6z17icUbDAyiagMIt6DkOjg4vlhOvAsVuH2nGLkbOC0h8qoouykhMp01HdCjJszpKueBcrg/0?wx_fmt=jpeg",
  "mp_name": "Insight数据库"
}